• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novartis

Pharma 50: Here’s how the world’s largest pharma companies are doing

May 12, 2021 By Chris Newmarker

Pharma 50 50 largest pharma companies pharmaceutical

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead. That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data […]

Filed Under: Featured, Pharmaceuticals Tagged With: AstraZeneca plc, Gilead Sciences, GlaxoSmithKline plc, Janssen Pharmaceuticals, Johnson & Johnson, Merck, Novartis, Pfizer Inc., Pharma 50, Roche, sanofi, Sinopharm

Valeo Pharma signs Canadian commercialization deal with Novartis

March 29, 2021 By Sean Whooley

Valeo Pharma Novartis

Valeo Pharma announced today that it entered into a commercialization and supply agreement with Novartis Canada for its asthma therapies. Montreal-based Valeo’s deal is to offer Canadian commercialization efforts for two asthma therapies: Enerzair Breezhaler (indacaterol as acetate, glycopyrronium as bromide and mometasone furoate, and Atectura Breezhaler (indacaterol as acetate and mometasone fuorate). Under the […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Novartis, Valeo Pharma

Pear Therapeutics closes $80M Series D

December 9, 2020 By Sean Whooley

Pear Therapeutics

Substance use and opioid use treatment developer Pear Therapeutics announced that it closed an $80 million Series D financing round. Existing investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox and EDBI contributed, as did new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management, according to a news […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup Tagged With: Novartis, opioids, peartherapeutics

Novartis unit spikes Pear Therapeutics deal

October 17, 2019 By Sean Whooley

Pear Therapeutics

Novartis (NYSE:NVS) unit Sandoz said this week that Pear Therapeutics will take sole responsibility for the commercialization of their prescription digital therapeutics program for treating substance and opioid use disorders. In April 2018, Pear announced that it agreed to deal commercialization rights of its digital therapeutics to Sandoz. The companies did not disclose financial details, but […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals Tagged With: Novartis, peartherapeutics, sandoz

Smiths Medical, United Therapeutics conspired to stifle generic Remodulin, Sandoz alleges

April 19, 2019 By Brad Perriello

gavel

Smiths Medical allegedly conspired with United Therapeutics to stifle a generic version of pulmonary arterial hypertension drug Remodulin, according to a lawsuit filed this week by Novartis (NYSE:NVS) unit Sandoz. The  Smiths Group (LON:SMIN) subsidiary, which is slated for a spinout as a separately traded company next year, makes the infusion pumps and single-use cartridges for […]

Filed Under: Featured, Legal News Tagged With: Novartis, sandoz, Smiths Group, Smiths Medical, United Therapeutics

Novartis launches COPD inhalers in China

March 22, 2019 By Sarah Faulkner

Novartis

Novartis (NYSE:NVS) has launched its Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease. The Ultibro Breezhaler system is a once-daily fixed-dose combination of indacaterol and glycopyrronium bromide. Seebri Breezhaler is a fixed-dose formulation of glycopyrronium bromide. The inhaled therapies are approved in more than 90 countries, including the U.S. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Novartis, soseigroup, Vectura

Rani debuts human trial data for robotic pill tech

March 1, 2019 By Sarah Faulkner

Rani Therapeutics

Rani Therapeutics this week touted the results of a first-in-human feasibility trial for its swallowable robotic pill, the RaniPill. Rani has developed a capsule that delivers an intestinal injection of medicine without exposing the drugs to digestive enzymes. The RaniPill device travels through the stomach and eventually reaches the intestine, where it injects the drug […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: AstraZeneca plc, Novartis, ranitherapeutics

Mylan wins race for generic Advair approval

January 31, 2019 By Nancy Crotti

Mylan logo - updated

FDA has approved the first generic of GlaxoSmithKline‘s (NYSE:GSK) blockbuster Advair respiratory drug, this one by Mylan (NSDQ:MYL), six months after rejecting Mylan’s application. Canonsburg, PA-based Mylan’s shares jumped 7% to $30.82 at market close after yesterday’s late-afternoon announcement, and were trading at $30.96 mid-morning today. GSK’s stock dipped 2% to$38.70 on the news late yesterday, but had […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Respiratory, Uncategorized, Wall Street Beat Tagged With: FDA, GlaxoSmithKline plc, Mylan, Novartis

Sandoz launches PFS alternative to epinephrine auto-injector

January 17, 2019 By Sarah Faulkner

Novartis' Sandoz division

Novartis (NYSE:NVS) division Sandoz said today that it launched its Symjepi epinephrine pre-filled syringe in the U.S. The company’s product is designed as an alternative to epinephrine auto-injectors to treat emergency allergic reactions. Sandoz described Symjepi as an “affordable” alternative to EpiPens but did not disclose the product’s price. “The Symjepi device is small in size and […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Novartis, sandoz

Novartis posts Q2 beat, promises to hold off on drug price hikes

July 18, 2018 By Sarah Faulkner

Novartis

Shares in Novartis (NYSE:NVS) were up today after the company beat expectations on Wall Street with its second-quarter financial results. The Switzerland-based company posted profits of $7.77 billion, or $3.34 per share, on sales of $13.16 billion for the three months ended June 30. Novartis saw its quarterly sales climb 7% compared with the same period […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Novartis

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 7
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS